Werner, Jan-Michael
Wolf, Lena
Tscherpel, Caroline
Bauer, Elena K.
Wollring, Michael
Ceccon, Garry
Deckert, Martina
Brunn, Anna
Pappesch, Roberto
Goldbrunner, Roland
Fink, Gereon R.
Galldiks, Norbert
Funding for this research was provided by:
Cologne Clinician Scientist-Program (CCSP) of the Deutsche Forschungsgemeinschaft (DFG, FI773/15-1)
Forschungszentrum Jülich GmbH
Article History
Received: 12 May 2022
Accepted: 9 June 2022
First Online: 18 June 2022
Declarations
:
: Related to the present work, the authors disclosed no potential conflicts of interest.
: The retrospective data collection and evaluation was approved by the Ethics Committee of the Faculty of Medicine of the University of Cologne. All procedures performed involving human participants followed the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent for regorafenib therapy had been obtained from all patients.